{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:21:19Z","timestamp":1771928479348,"version":"3.50.1"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the existence of antiphospholipid antibodies (aPL) has been extensively documented as a risk factor for thrombocytopenia, hemolytic anemia, and recurrent miscarriage, their contribution to renal damage in the context of the systemic lupus erythematosus (SLE) is yet to be defined. This meta-analysis investigated the association between aPL and renal injury among patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted to determine publications that examined the relationship between the level of aPL and renal functioning in SLE patients in four electronic databases (PubMed, Cochrane Library, Embase, and Web of Science). Funnel plots and Egger\u2019s test were utilized to assess the presence of publication bias. Sensitivity analysis and the trim-and-fill method were used in the evaluation of the stability of the results. Subgroup analyses were performed according to study design, geographic region, aPL subtype, publication date, and pathological type of lupus nephritis. Also, the cumulative meta-analyses were conducted by ranking the studies based on the year of publication, sample size, and the Newcastle-Ottawa Scale score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 34,353 publications were retrieved up to September 12, 2025. After screening, a total of 70 studies (18 case-control, 23 cohort, and 29 cross-sectional) involving 12,456 SLE patients were included. The pooled OR for renal injury in aPL\u2212positive versus aPL\u2212negative patients was 2.09 (1.70\u20132.58). Subgroup analysis revealed anti-cardiolipin (aCL), lupus anticoagulant (LA), and antiphospholipid syndrome significantly increased the risk of renal injury compared with control groups, 108with OR of 1.71 (1.34\u20132.18), 2.43 (1.64\u20133.61), 2.07 (1.48\u20132.89), respectively. In contrast, no statistically significant increase in renal injury risk was observed in groups positive for anti-\u03b22-glycoprotein I and aPS\/PT. Cumulative meta-analyses consistently demonstrated an increased risk of renal injury in aPL-positive patients, and this association remained stable across different publication years, sample sizes, and study quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Seropositivity for aPL was significantly associated with an increased risk of renal injury in SLE patients, primarily driven by LA and aCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1734274","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:10Z","timestamp":1770096130000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-phospholipid antibodies as a risk factor for renal injury in patients with systemic lupus erythematosus: a comprehensive analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzi","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First People\u2019s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology","place":["Kunming, Yunnan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lefeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Translational Medicine, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingcheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01667","article-title":"Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.autrev.2016.01.018","article-title":"The hidden world of anti-phospholipid antibodies and female infertility: A literature appraisal","volume":"15","author":"Chighizola","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0325-RSR.1","article-title":"Antiphospholipid antibody syndrome","volume":"135","author":"Sangle","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102913","DOI":"10.3390\/ijms23084151","article-title":"Antiphospholipid antibodies and lipids in hematological Malignancies","volume":"23","author":"Barreno-Rocha","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102913","DOI":"10.1016\/j.autrev.2021.102913","article-title":"Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"21","author":"Bernardoff","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.autrev.2019.102395","article-title":"Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"18","author":"Chock","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169432","article-title":"IgA antiphospholipid antibodies in antiphospholipid syndrome and systemic lupus erythematosus","volume":"23","author":"Reshetnyak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01181","article-title":"Antiphospholipid syndrome nephropathy: from pathogenesis to treatment","volume":"9","author":"Tektonidou","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000425","article-title":"Renal thrombotic microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: A case-control study","volume":"22","author":"Barrera-Vargas","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1186\/ar2736","article-title":"Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases","volume":"11","author":"Zheng","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12445","article-title":"Antiphospholipid antibodies are associated with low levels of complement C3 and C4 in patients with systemic lupus erythematosus","volume":"84","author":"Garabet","year":"2016","journal-title":"Scand J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.7.457","article-title":"The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury","volume":"93","author":"Griffiths","year":"2000","journal-title":"Qjm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103158","DOI":"10.1016\/j.autrev.2022.103158","article-title":"Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"21","author":"Domingues","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jre.13405","article-title":"Risk of bias evaluation of cross-sectional studies: adaptation of the newcastle-ottawa scale","author":"Carra","year":"2025","journal-title":"J Periodontal Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00698-9","article-title":"Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis","volume":"33","author":"Sciascia","year":"2020","journal-title":"J Nephrology."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14194","article-title":"Anti-C1q antibodies in lupus nephritis children with glomerular microthrombosis","volume":"28","author":"Zhang","year":"2023","journal-title":"Nephrology."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.556","article-title":"Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis","volume":"62","author":"Alba","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb05714.x","article-title":"Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis","volume":"85","author":"D\u2019Cruz","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000013615","article-title":"Anticardiolipin antibodies in South African patients with lupus nephritis: A clinical and renal pathological study","volume":"20","author":"Naiker","year":"2000","journal-title":"Am J Nephrology."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.2363","article-title":"Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis","volume":"48","author":"Tsuruta","year":"2009","journal-title":"Internal Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158076","article-title":"Antiphospholipid antibodies in lupus nephritis","volume":"11","author":"Parodis","year":"2016","journal-title":"PloS One"},{"key":"B29","article-title":"Antiphospholipid antibody and childhood lupus nephritis","volume":"29","author":"Zhong","year":"2011","journal-title":"J Clin Pediatrics."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2018.25.4.239","article-title":"Antiphospholipid antibody positivity and the clinical outcomes of patients with systemic lupus erythematosus","volume":"25","author":"Nam","year":"2018","journal-title":"J Rheumatic Diseases."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2900-3","article-title":"Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study","volume":"34","author":"Erre","year":"2014","journal-title":"Rheumatol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheumatism."},{"key":"B34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-\u03b22 glycoprotein i antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13733","article-title":"Association between antiphospholipid antibodies and factor Bb in lupus nephritis patients with glomerular microthrombosis","volume":"22","author":"Zhou","year":"2019","journal-title":"Int J Rheumatic Diseases."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.6.401","article-title":"Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis","volume":"91","author":"Bhandari","year":"1998","journal-title":"QJM: Int J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/acr.2220010.1002\/acr.22200","article-title":"Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients","volume":"66","author":"Jordan","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-3606.2015.03.008","article-title":"Associations of anticardiolipin antibody with systemic lupus erythematosus and lupus nephritis in children","volume":"33","author":"Cui","year":"2015","journal-title":"J Clin Pediatrics."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151395","article-title":"Beta2-glycoprotein I expression in lupus nephritis patients with antiphospholipid-associated nephropathy","volume":"43","author":"Gao","year":"2016","journal-title":"J Rheumatol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7705\/biomedica.v23i3.1223","article-title":"Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia","volume":"23","author":"Anaya","year":"2003","journal-title":"Biom\u00e9dica: Rev del Instituto Nacional Salud."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.4078\/jrd.2023.0065","article-title":"Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus","volume":"31","author":"Al-Mayouf","year":"2024","journal-title":"J Rheumatic Diseases."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092117","article-title":"Clinical features and survival analysis of lupus nephritis among patients with systemic lupus erythematosus: A three-decade-long retrospective cohort study","volume":"12","author":"Perge","year":"2024","journal-title":"Biomedicines."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000421701","article-title":"Clinical implication of antiphospholipid antibodies in systemic lupus erythematosus","volume":"99","author":"Stratta","year":"1992","journal-title":"Contrib Nephrol."},{"key":"B45","article-title":"Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies","volume":"20","author":"\u0160ipek-Dolni\u010dar","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2008.12.011","article-title":"Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE)","volume":"5","author":"Miranda","year":"2009","journal-title":"Reumatologia Clinica."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2012.01.001","article-title":"Comparative study of kidney affection in SLE patients with and without antiphospholipid syndrome","volume":"34","author":"Gaber","year":"2012","journal-title":"Egyptian Rheumatologist."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/jcm13154486","article-title":"Comparison of clinical and laboratory characteristics in lupus nephritis vs. Non-lupus nephritis patients\u2014A comprehensive retrospective analysis based on 921 patients","volume":"13","author":"Kosa\u0142ka-W\u0119giel","year":"2024","journal-title":"J Clin Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.8.863","article-title":"Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone","volume":"40","author":"Moss","year":"2001","journal-title":"Rheumatol (Oxford)."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-484X.2022.24.017","article-title":"Correlation between antiphospholipid antibodies and lupus nephritis","volume":"38","author":"Yu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088740","article-title":"Delayed lupus nephritis","volume":"67","author":"Varela","year":"2008","journal-title":"Ann Rheumatic Diseases."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02870311","article-title":"Evaluation of clinical outcomes and renal vascular pathology among patients with lupus","volume":"7","author":"Barber","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00005792-198103000-00001","article-title":"Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance","volume":"60","author":"Kant","year":"1981","journal-title":"Med (Baltimore)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-015-0614-5","article-title":"Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: An observational cross-sectional study with longitudinal follow-up","volume":"17","author":"Gerhardsson","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B55","article-title":"Histological features of antiphospholipid nephropathy in patients with systemic lupus erythematosus","volume":"25","author":"Naseeb","year":"2015","journal-title":"J Coll Physicians Surgeons Pakistan."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100650","article-title":"IgM anti-\u03b22 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus","volume":"38","author":"Mehrani","year":"2011","journal-title":"J Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep152","article-title":"Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies","volume":"48","author":"Galindo","year":"2009","journal-title":"Rheumatology."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.121286","article-title":"Immunological aspects of biopsy-proven lupus nephritis in Bahraini patients with systemic lupus erythematosus","volume":"24","author":"Farid","year":"2013","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"B59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejr.2016.05.007","article-title":"Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients","volume":"39","author":"Gamal","year":"2017","journal-title":"Egyptian Rheumatologist."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpam.2015.08.002","article-title":"The impact of antiphospholipid antibodies in children with lupus nephritis","volume":"2","author":"Al-Mayouf","year":"2015","journal-title":"Int J Pediatr Adolesc Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.14.3","article-title":"The importance of serological and histopathological diagnosis of the different forms of systemic lupus erythematosus with and without lupus nephritis","volume":"9","author":"Wis\u0142owska","year":"2014","journal-title":"Int J Clin Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.621590","article-title":"Incidence of a first thrombo-embolic event in patients with systemic lupus erythematosus and anti-phosphatidylserine\/prothrombin antibodies: A prospective study","volume":"8","author":"Sciascia","year":"2021","journal-title":"Front Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70258-5","article-title":"Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study","volume":"20","author":"Farrugia","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Silvari\u00f1o","year":"2011","journal-title":"Lupus."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem335","article-title":"Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies","volume":"47","author":"Descloux","year":"2008","journal-title":"Rheumatol (Oxford)."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/art.23662","article-title":"Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2007.00792.x","article-title":"Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies","volume":"12","author":"Cheunsuchon","year":"2007","journal-title":"Nephrol (Carlton)."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317692419","article-title":"Prognostic significance of renal vascular pathology in lupus nephritis","volume":"26","author":"Mej\u00eda-Vilet","year":"2017","journal-title":"Lupus."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122796","article-title":"Recurrent lupus nephritis after kidney transplantation: A surveillance biopsy study","volume":"69","author":"Norby","year":"2010","journal-title":"Ann Rheumatic Diseases."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/096120339400300106","article-title":"Renal biopsy in systemic lupus erythematosus: Significance of glomerular thrombosis","volume":"3","author":"Miranda","year":"1994","journal-title":"Anal 108 cases. Lupus."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199709000-00003","article-title":"Renal vascular lesions in lupus nephritis","volume":"76","author":"Descombes","year":"1997","journal-title":"Medicine."},{"key":"B73","article-title":"The risk factors for Chinese patients with lupus nephritis","author":"Luo","year":"2004","journal-title":"J Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1159\/000188671","article-title":"The role of antiphospholipid antibodies in lupus nephropathy","volume":"71","author":"Perdiguero","year":"1995","journal-title":"Nephron."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmab096","article-title":"Semaphorin 3A levels in lupus with and without secondary antiphospholipid antibody syndrome and renal involvement","volume":"53","author":"Bayram","year":"2022","journal-title":"Lab Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.155","article-title":"Significance of anti-phospholipid antibodies in patients with lupus nephritis","volume":"39","author":"Frampton","year":"1991","journal-title":"Kidney Int"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.9.962","article-title":"Significance of anticardiolipin and anti-\u03b22-glycoprotein I antibodies in lupus nephritis","volume":"39","author":"Loizou","year":"2000","journal-title":"Rheumatology."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500113","article-title":"The significance of anticardiolipin antibodies in patients with lupus nephritis","volume":"5","author":"Abu-Shakra","year":"1996","journal-title":"Lupus."},{"key":"B79","article-title":"Significance of antiphospholipid antibodies in lupus nephritis","author":"Natejumnong","year":"2006","journal-title":"J Med Assoc Thailand = Chotmaihet thangphaet."},{"key":"B80","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu530xx","article-title":"Systemic lupus erythematosus in Tunisia: Demographic and clinical analysis of 100 patients","volume":"13","author":"Houman","year":"2004","journal-title":"Lupus."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360080059007","article-title":"Thrombosis in systemic lupus erythematosus: relation to the presence of circulating anticoagulants","volume":"145","author":"Glueck","year":"1985","journal-title":"Arch Internal Med"},{"key":"B83","article-title":"Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome","volume":"33","author":"Hernandez-Molina","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318809177","article-title":"Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies","volume":"27","author":"Shah","year":"2018","journal-title":"Lupus."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310376523","article-title":"Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy","volume":"19","author":"Hu","year":"2010","journal-title":"Lupus."},{"key":"B86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/94.1.19","article-title":"Cardiovascular risk factors and the long-term outcome of lupus nephritis","volume":"94","author":"Font","year":"2001","journal-title":"Qjm."},{"key":"B87","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar3856","article-title":"Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis","volume":"14","author":"Gonzalo","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314531839","article-title":"Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome","volume":"23","author":"De\u00e1k","year":"2014","journal-title":"Lupus."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"103072","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.8.4209","article-title":"Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells","volume":"168","author":"Cho","year":"2002","journal-title":"J Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308093553","article-title":"Autoimmune-mediated atherothrombosis","volume":"17","author":"Matsuura","year":"2008","journal-title":"Lupus."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084200","article-title":"Platelets and the antiphospholipid syndrome","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S527859","article-title":"Anti-PS igG immune complexes impair macrophage phagocytosis in SLE via LOX-dependent oxidative stress","volume":"18","author":"Guan","year":"2025","journal-title":"J Inflammation Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914526","article-title":"Lupus nephritis risk factors and biomarkers: an update","volume":"24","author":"Renaudineau","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome","volume":"111","author":"Sciascia","year":"2014","journal-title":"A systematic review. Thromb Haemost."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213846","article-title":"Management of antiphospholipid syndrome","volume":"78","author":"Uthman","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:30:02Z","timestamp":1771925402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2026.1734274"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1734274","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1734274"}}